

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Briefing

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

Prostate cancer is the most common cancer in men, accounting for approximately 25% of new diagnoses of cancer in men and 12% of all cancers. Prostate cancer increases with age. Most cases develop in men aged 70 or older. In the UK, men of African-Caribbean or African descent have approximately two to three times the risk of being diagnosed or dying from prostate cancer than white men. Asian men generally have a lower risk than the national average.

There is a higher incidence of prostate cancer in the less socio-economically deprived areas, which is assumed to be due to higher rates of prostate specific antigen (PSA) testing among affluent men

All people with cancer are covered by the disability provision of the Equality Act 2010 from the point of diagnosis.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?

This was not thought to have an impact on the assessment of the procedure. No exclusions were applied.

3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the committee meeting, and, if so, have changes to the stakeholder list been made?’

No

Kevin Harris

Approved by Programme Director and Clinical Advisor

Date: 30/11/2022

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

No specific data relating to the potential equality issues were identified in the literature presented in the overview.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?

No

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?
No

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE's obligation to promote equality?
Not applicable

6. Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?
Not applicable

Kevin Harris

Approved by Programme Director and Clinical Advisor

Date: 30/11/2022

Final interventional procedures document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
No

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to access for the specific group?
Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 2, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

No

Anastasia Chalkidou

Approved by Associate Director

Date: 02/12/2022